Exploring protein kinase inhibitors: unveiling gemcitabine resistance in pancreatic cancer

Pancreas. 2012 Jul;41(5):804-5. doi: 10.1097/MPA.0b013e31823f3fcb.
No abstract available

Publication types

  • Letter
  • Research Support, N.I.H., Extramural

MeSH terms

  • Antimetabolites, Antineoplastic / administration & dosage
  • Antimetabolites, Antineoplastic / pharmacology
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use
  • Cell Line, Tumor
  • Cell Survival / drug effects
  • Deoxycytidine / administration & dosage
  • Deoxycytidine / analogs & derivatives*
  • Deoxycytidine / pharmacology
  • Drug Resistance, Neoplasm / drug effects*
  • Drug Synergism
  • Gemcitabine
  • Humans
  • Pancreatic Neoplasms / drug therapy
  • Pancreatic Neoplasms / metabolism
  • Pancreatic Neoplasms / pathology
  • Protein Kinase Inhibitors / administration & dosage
  • Protein Kinase Inhibitors / pharmacology*
  • Protein Kinases / metabolism

Substances

  • Antimetabolites, Antineoplastic
  • Protein Kinase Inhibitors
  • Deoxycytidine
  • Protein Kinases
  • Gemcitabine